CJC-1295 Side Effects
CJC-1295 side effects — the common GH-elevation reactions, the DAC-vs-no-DAC difference that matters most for safety, who should avoid it, and how to reduce them.
CJC-1295 is a GHRH analog, so its side effects are the growth-hormone-elevation class effects: water retention, injection-site reactions, flushing, occasional headache, and paresthesia (tingling) at higher GH exposure. The most safety-relevant choice is DAC vs no-DAC: the DAC form's ~8-day sustained elevation can downregulate GH-receptor sensitivity, while the no-DAC form (Mod GRF 1-29) preserves natural pulses. As a GH secretagogue it shares the cancer, diabetes, and pregnancy cautions.
The honest starting point on CJC-1295 side effects: as a GHRH analog, its effects are the growth-hormone-elevation class effects — water retention, injection-site reactions, flushing, and paresthesia — most of them mild and dose-dependent. The single most safety-relevant decision is DAC vs no-DAC: the no-DAC form preserves natural GH pulses, while the DAC form’s multi-day sustained elevation is the main mechanism-level concern. The sections below cover common and serious effects, the growth-hormone-axis contraindications, and how to reduce your risk.
Common side effects
| Effect | Frequency | Notes |
|---|---|---|
| Water retention | Common, dose-dependent | The most frequently reported effect |
| Injection-site reactions | Common, mild | Redness that fades within an hour |
| Flushing | Occasional | Shortly after injection |
| Headache | Occasional | Usually transient, first 1–2 weeks |
| Tingling / numbness (paresthesia) | Occasional | From GH elevation; carpal-tunnel-like symptoms at higher exposure |
Serious & rare effects
- Allergic reaction — Rare — facial/throat swelling, hives, or difficulty breathing require emergency care
- Sustained GH-receptor downregulation (DAC form) — The DAC form's multi-day elevation is non-pulsatile and can blunt receptor sensitivity over time — the main reason many prefer no-DAC
- Injection-site infection — Technique-related — spreading redness, heat, pus, or fever
Who should avoid it
- Active or suspected cancer — elevated GH/IGF-1 can promote tumor growth
- Uncontrolled diabetes — GH is diabetogenic and can worsen insulin resistance
- Active pituitary disorders
- Pregnancy and breastfeeding — no safety data
Feeling something? Check here
- Mild flushing or warmth shortly after injection
- Transient injection-site redness that fades within an hour
- Mild early water retention that settles as you titrate
- Persistent water retention, headache, or tingling/numbness in the hands — reduce toward a lower dose
- Joint stiffness (carpal-tunnel-like) at higher doses — lower the dose and reassess
- Injection-site lumps lasting more than a day — rotate sites, check technique
- Facial/throat swelling, difficulty breathing, hives — stop and seek emergency care
- Signs of injection-site infection — spreading redness, heat, pus, fever
GH-secretagogue tolerability from the cited literature; CJC-1295 produced dose-dependent GH/IGF-1 elevation in healthy adults (Teichman et al., 2006). A single 2006 DAC-form trial death was attributed to pre-existing cardiac disease with no causal link established.
This self-check is educational, not a diagnosis. When in doubt, stop dosing and consult a qualified healthcare provider.
How to reduce side effects
- Prefer the no-DAC form (Mod GRF 1-29) to preserve natural pulsatile GH release and avoid the DAC form's sustained-elevation receptor downregulation
- Start low (100 mcg) and titrate; water retention and paresthesia are dose-dependent GH signals
- Dose at bedtime on an empty stomach to align with the natural GH pulse
- Monitor IGF-1 every 4–6 weeks on longer protocols; target upper-normal for age